Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Cash from Financing Activities (2016 - 2025)

Marimed (MRMD) has disclosed Cash from Financing Activities for 12 consecutive years, with -$1.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities fell 285.82% to -$1.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$4.7 million, a 155.65% decrease, with the full-year FY2024 number at $3.0 million, down 87.01% from a year prior.
  • Cash from Financing Activities was -$1.7 million for Q3 2025 at Marimed, down from -$806000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $23.3 million in Q1 2023 to a low of -$3.1 million in Q3 2023.
  • A 5-year average of $1.5 million and a median of -$286000.0 in 2021 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: tumbled 1349.15% in 2022, then skyrocketed 7176.6% in 2023.
  • Marimed's Cash from Financing Activities stood at -$286000.0 in 2021, then crashed by 109.79% to -$600000.0 in 2022, then skyrocketed by 850.0% to $4.5 million in 2023, then tumbled by 119.84% to -$893000.0 in 2024, then tumbled by 90.82% to -$1.7 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Cash from Financing Activities are -$1.7 million (Q3 2025), -$806000.0 (Q2 2025), and -$1.3 million (Q1 2025).